ABVX
ABVX clinical trials: Abivax S.A.
Every trial on ClinicalTrials.gov where Abivax S.A. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 23
- Trials linked
- 23
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
ABVX on the catalyst calendar · ABVX registry changes
- Primary completion Apr 2027Sponsor estimatePhase 1NCT07453784Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet FormulationAbivax S.A. · HealthyRecruitingABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 14, 2022ActualPhase 1/Phase 2NCT03897543ABX196 in Combination With Nivolumab in Patients With Hepatocellular CarcinomaAbivax S.A. · Carcinoma, HepatocellularCompletedABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 24, 2025ActualPhase 3NCT05507216ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2Abivax S.A. · Ulcerative ColitisCompletedABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 24, 2025ActualPhase 3NCT05507203ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1Abivax S.A. · Ulcerative ColitisCompletedABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 18, 2021ActualPhase 1NCT05121714Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464Abivax S.A. · HealthyCompletedABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 28, 2026ActualPhase 3NCT05535946ABTECT - MaintenanceAbivax S.A. · Ulcerative ColitisActive, not recruitingABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT06456593Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's DiseaseAbivax S.A. · Moderately to Severely Active Crohn DiseaseRecruitingABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2028Sponsor estimatePhase 2NCT05177835Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative ColitisAbivax S.A. · Ulcerative ColitisActive, not recruitingABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 23, 2023ActualPhase 2NCT04023396Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative ColitisAbivax S.A. · Ulcerative ColitisCompletedABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 5, 2021ActualPhase 2/Phase 3NCT04393038ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19Abivax S.A. · COVID-19TerminatedABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 23, 2023ActualPhase 2NCT04049448Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid ArthritisAbivax S.A. · Rheumatoid ArthritisCompletedABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 1, 2021ActualPhase 2NCT03760003Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative ColitisAbivax S.A. · Ulcerative ColitisCompletedABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 12, 2022ActualPhase 2NCT03368118Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative ColitisAbivax S.A. · Ulcerative ColitisCompletedABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 19, 2022Sponsor estimatePhase 2/Phase 3NCT03905109Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease PatientsAbivax S.A. · Crohn DiseaseWithdrawnABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 25, 2018ActualPhase 2NCT03093259ABX464 in Subjects With Moderate to Severe Active Ulcerative ColitisAbivax S.A. · Ulcerative ColitisCompletedABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2014ActualPhase 1NCT02792686ABX464 First in Man StudyAbivax S.A. · Healthy VolunteersCompletedABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 30, 2017ActualPhase 2NCT02735863ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor TreatmentAbivax S.A. · HIV InfectionCompletedABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 27, 2018ActualPhase 1/Phase 2NCT02990325A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive AdultsAbivax S.A. · HIV InfectionsCompletedABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 27, 2021ActualPhase 2NCT03813199Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid ArthritisAbivax S.A. · Rheumatoid ArthritisCompletedABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 18, 2022ActualPhase 1NCT05032560Safety and Pharmacokinetics Study in Healthy Japanese VolunteersAbivax S.A. · Healthy VolunteersCompletedABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2016ActualPhase 2/Phase 3NCT02249988Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis BAbivax S.A. · Chronic Hepatitis BCompletedABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2015ActualPhase 2NCT02452242Safety, PK and PD Study of ABX464 in Untreated HIV PatientsAbivax S.A. · Human Immunodeficiency Virus InfectionsCompletedABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2015ActualPhase 1NCT02731885Food Effect on Pharmacokinetic Parameters of ABX464Abivax S.A. · Healthy VolunteersCompletedABVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 23 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner